Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06245213 · ClinicalTrials.gov registry record · Phase 2
A Study of ANAVEX3-71 in Adults With Schizophrenia
A Phase 2 study of Schizophrenia, sponsored by Anavex Life Sciences.
- Active
- Registry status
- Phase 2
- Development phase
- 71
- Enrollment target
- 1
- Study location
NCT06245213 is a Phase 2 study of Schizophrenia that is active but no longer recruiting, run by Anavex Life Sciences. The registered enrollment target is 71 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (68% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06245213, a Phase 2 study of Schizophrenia, is active but no longer recruiting, sponsored by Anavex Life Sciences.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 71 participants
- Enrollment target
- 1
- Study location
Study Summary
A study to evaluate the safety, tolerability, efficacy, pharmacokinetics, and electrophysiology of ANAVEX3-71 in patients with Schizophrenia.
Conditions Studied
Interventions
- DRUG ANAVEX3-71 oral capsules
- DRUG Placebo oral capsules
Study Locations (1)
New Jersey
- CenExel Hassman Research Institute - Marlton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 71 participants |
| Start Date | 2024-03-15 |
| Est. Completion | 2025-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06245213
The ClinicalTrials.gov registry entry for NCT06245213 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 71 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (68% lower). The listed sponsor is Anavex Life Sciences, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 2 interventions - of which ANAVEX3-71 oral capsules is the first listed.
NCT06245213 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT06245213 about?
NCT06245213 is a clinical study titled "A Study of ANAVEX3-71 in Adults With Schizophrenia". A study to evaluate the safety, tolerability, efficacy, pharmacokinetics, and electrophysiology of ANAVEX3-71 in patients with Schizophrenia.
What is the current status of trial NCT06245213?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 71 participants. The study started on 2024-03-15. Estimated completion is 2025-06-30.
What conditions does trial NCT06245213 study?
This clinical trial studies the following conditions: Schizophrenia.
What interventions are being tested in trial NCT06245213?
The interventions under investigation include: ANAVEX3-71 oral capsules (DRUG), Placebo oral capsules (DRUG).
Who is sponsoring clinical trial NCT06245213?
This trial is sponsored by Anavex Life Sciences, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06245213 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Search for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness
RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia
RECRUITING · Phase 2
-
Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia
RECRUITING · Phase 2
-
A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With Schizophrenia
RECRUITING · Phase 2
-
Low-dose Buprenorphine as a Modulator of Social Motivation in Schizophrenia
RECRUITING · Phase 2
-
Study of ALTO-101 in Patients With Schizophrenia
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.